SCHEMBL25213499

SCHEMBL25213499

O=C(O)c1cc(-c2ccc(/C=C3\Oc4ccccc4C3=O)o2)ccc1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.71
PTPN22 Q9Y2R2 5/20 0.64
PTPN5 P54829 2/20 0.64
PTPN1 P18031 1/20 0.64
PTPN7 P35236 1/20 0.64
DUSP3 P51452 1/20 0.64
LDHA P00338 1/20 0.57
LDHB P07195 1/20 0.57
HAO1 Q9UJM8 1/20 0.57
IGF1R P08069 2/20 0.53
INSR P06213 1/20 0.53
STK17B O94768 4/20 0.50
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25270155 1.00 AKT1 (0.71) AKT1PTPN22PTPN5PTPN1PTPN7
SCHEMBL26168407 0.85 AKT1 (0.55) AKT1PTPN22PTPN5PTPN1PTPN7
SCHEMBL6720217 0.83 AKT1 (1.00) AKT1PTPN22PTPN5PTPN1PTPN7
SCHEMBL31358662 0.83 AKT1 (1.00) AKT1PTPN22PTPN5PTPN1PTPN7
SCHEMBL10921543 0.79 STK17B (0.74) AKT1IGF1RSTK17BHDAC3HDAC4
SCHEMBL25420537 0.78 AKT1 (0.70) AKT1PTPN22PTPN5PTPN1PTPN7
SCHEMBL25248130 0.78 PTPN22 (1.00) AKT1PTPN22PTPN5PTPN1PTPN7
SCHEMBL14444606 0.78 PTPN22 (1.00) AKT1PTPN22PTPN5PTPN1PTPN7
SCHEMBL31358822 0.78 AKT1 (0.70) AKT1PTPN22PTPN5PTPN1PTPN7
SCHEMBL25248127 0.78 PTPN22 (1.00) AKT1PTPN22PTPN5PTPN1PTPN7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed
WO-2023091674-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-05-25 WO disclosed
WO-2023091674-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 AKT1 194/4885PTPN22 5/4885PTPN5 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.